188 related articles for article (PubMed ID: 37026013)
21. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.
Moriyama S; Adachi Y; Sato T; Tonouchi K; Sun L; Fukushi S; Yamada S; Kinoshita H; Nojima K; Kanno T; Tobiume M; Ishijima K; Kuroda Y; Park ES; Onodera T; Matsumura T; Takano T; Terahara K; Isogawa M; Nishiyama A; Kawana-Tachikawa A; Shinkai M; Tachikawa N; Nakamura S; Okai T; Okuma K; Matano T; Fujimoto T; Maeda K; Ohnishi M; Wakita T; Suzuki T; Takahashi Y
Immunity; 2021 Aug; 54(8):1841-1852.e4. PubMed ID: 34246326
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T
J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 spike HexaPro formulated in aluminium hydroxide and administered in an accelerated vaccination schedule partially protects Syrian Hamsters against viral challenge despite low neutralizing antibody responses.
Christensen D; Polacek C; Sheward DJ; Hanke L; McInerney G; Murrell B; Hartmann KT; Jensen HE; Zimmermann J; Jungersen G; Illigen KE; Isling LK; Fernandez-Antunez C; Ramirez S; Bukh J; Pedersen GK
Front Immunol; 2023; 14():941281. PubMed ID: 36756130
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of a panel of therapeutic antibody clinical candidates for efficacy against SARS-CoV-2 in Syrian hamsters.
Cong Y; Mucker EM; Perry DL; Dixit S; Kollins E; Byrum R; Huzella L; Kim R; Josleyn M; Kwilas S; Stefan C; Shoemaker CJ; Koehler J; Coyne S; Delp K; Liang J; Drawbaugh D; Hischak A; Hart R; Postnikova E; Vaughan N; Asher J; St Claire M; Hanson J; Schmaljohn C; Eakin AE; Hooper JW; Holbrook MR
Antiviral Res; 2023 May; 213():105589. PubMed ID: 37003305
[TBL] [Abstract][Full Text] [Related]
25. SARS-CoV-2 neutralizing capacity among blood donors without prior COVID-19 symptomatic history vs. blood donors with prior COVID-19 symptomatic history: A comparative study.
Ravula U; Chunchu SR; Mooli S; Naik R; Sarangapati PRR
Transfus Clin Biol; 2022 May; 29(2):107-111. PubMed ID: 35167958
[TBL] [Abstract][Full Text] [Related]
26. Pan-neutralizing, germline-encoded antibodies against SARS-CoV-2: Addressing the long-term problem of escape variants.
Lunderberg JM; Dutta S; Collier AY; Lee JS; Hsu YM; Wang Q; Zheng W; Hao S; Zhang H; Feng L; Robson SC; Gao W; Riedel S
Front Immunol; 2022; 13():1032574. PubMed ID: 36389829
[TBL] [Abstract][Full Text] [Related]
27. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
28. Reduced SARS-CoV-2 disease outcomes in Syrian hamsters receiving immune sera: Quantitative image analysis in pathologic assessments.
Piedra-Mora C; Robinson SR; Tostanoski LH; Dayao DAE; Chandrashekar A; Bauer K; Wrijil L; Ducat S; Hayes T; Yu J; Bondzie EA; McMahan K; Sellers D; Giffin V; Hope D; Nampanya F; Mercado NB; Kar S; Andersen H; Tzipori S; Barouch DH; Martinot AJ
Vet Pathol; 2022 Jul; 59(4):648-660. PubMed ID: 35521761
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model.
Haagmans BL; Noack D; Okba NMA; Li W; Wang C; Bestebroer T; de Vries R; Herfst S; de Meulder D; Verveer E; van Run P; Lamers MM; Rijnders B; Rokx C; van Kuppeveld F; Grosveld F; Drabek D; Geurts van Kessel C; Koopmans M; Bosch BJ; Kuiken T; Rockx B
J Infect Dis; 2021 Jun; 223(12):2020-2028. PubMed ID: 34043806
[TBL] [Abstract][Full Text] [Related]
30. Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy.
Gontu A; Srinivasan S; Salazar E; Nair MS; Nissly RH; Greenawalt D; Bird IM; Herzog CM; Ferrari MJ; Poojary I; Katani R; Lindner SE; Minns AM; Rossi R; Christensen PA; Castillo B; Chen J; Eagar TN; Yi X; Zhao P; Leveque C; Olsen RJ; Bernard DW; Gollihar J; Kuchipudi SV; Musser JM; Kapur V
Commun Biol; 2021 Feb; 4(1):267. PubMed ID: 33627795
[TBL] [Abstract][Full Text] [Related]
31. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants.
Ku Z; Xie X; Hinton PR; Liu X; Ye X; Muruato AE; Ng DC; Biswas S; Zou J; Liu Y; Pandya D; Menachery VD; Rahman S; Cao YA; Deng H; Xiong W; Carlin KB; Liu J; Su H; Haanes EJ; Keyt BA; Zhang N; Carroll SF; Shi PY; An Z
Nature; 2021 Jul; 595(7869):718-723. PubMed ID: 34082438
[TBL] [Abstract][Full Text] [Related]
32. Convalescent plasma for COVID-19: Donor demographic factors associated high neutralising antibody titres.
Mehew J; Johnson R; Roberts D; Griffiths A; Harvala H
Transfus Med; 2022 Aug; 32(4):327-337. PubMed ID: 35434868
[TBL] [Abstract][Full Text] [Related]
33. Long-term immunity in convalescent Syrian hamsters provides protection against new-variant SARS-CoV-2 infection of the lower but not upper respiratory tract.
Stauft CB; Selvaraj P; Lien CZ; Starost MF; Wang TT
J Med Virol; 2022 Jun; 94(6):2833-2836. PubMed ID: 35128693
[TBL] [Abstract][Full Text] [Related]
34. Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera.
Espeseth AS; Yuan M; Citron M; Reiserova L; Morrow G; Wilson A; Horton M; Rukhman M; Kinek K; Hou F; Li SL; Li F; Choi Y; Heidecker G; Luo B; Wu G; Zhang L; Strable E; DeStefano J; Secore S; Mukhopadhyay TK; Richardson DD; Sayeed E; Welch LS; Bett AJ; Feinberg MB; Gupta SB; Cooper CL; Parks CL
EBioMedicine; 2022 Aug; 82():104203. PubMed ID: 35915046
[TBL] [Abstract][Full Text] [Related]
35. Omicron variants escape the persistent SARS-CoV-2-specific antibody response in 2-year COVID-19 convalescents regardless of vaccination.
Wang M; Zhou B; Fan Q; Zhou X; Liao X; Lin J; Ma Z; Dong J; Wang H; Ge X; Ju B; Zhang Z
Emerg Microbes Infect; 2023 Dec; 12(1):2151381. PubMed ID: 36444724
[TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.
Guo L; Wang G; Wang Y; Zhang Q; Ren L; Gu X; Huang T; Zhong J; Wang Y; Wang X; Huang L; Xu L; Wang C; Chen L; Xiao X; Peng Y; Knight JC; Dong T; Cao B; Wang J
Lancet Microbe; 2022 May; 3(5):e348-e356. PubMed ID: 35345417
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic accuracy of three SARS-CoV2 antibody detection assays, neutralizing effect and longevity of serum antibodies.
Bubonja-Šonje M; Batičić L; Abram M; Cekinović Grbeša Đ
J Virol Methods; 2021 Jul; 293():114173. PubMed ID: 33930473
[TBL] [Abstract][Full Text] [Related]
38. Isotyping and quantitation of the humoral immune response to SARS-CoV-2.
Goyins KA; Yu JJ; Papp SB; Beddard R; Murthy AK; Chambers JP; Arulanandam BP
Exp Biol Med (Maywood); 2022 Jun; 247(12):1055-1060. PubMed ID: 35369776
[TBL] [Abstract][Full Text] [Related]
39. Immune durability and protection against SARS-CoV-2 re-infection in Syrian hamsters.
Field CJ; Heinly TA; Patel DR; Sim DG; Luley E; Gupta SL; Vanderford TH; Wrammert J; Sutton TC
Emerg Microbes Infect; 2022 Dec; 11(1):1103-1114. PubMed ID: 35333692
[TBL] [Abstract][Full Text] [Related]
40. Over 1-year duration and age difference of SARS-CoV-2 antibodies in convalescent COVID-19 patients.
Zeng F; Wu M; Wang J; Li J; Hu G; Wang L
J Med Virol; 2021 Dec; 93(12):6506-6511. PubMed ID: 34170519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
